Feasibility and efficacy of definitive radiotherapy with 66 GY and concurrent carboplatin-paclitaxel chemotherapy for stage Ⅲ non-small cell lung cancer.

• 資料種別: 博士論文
• タイトル: Feasibility and efficacy of definitive radiotherapy with 66 GY and concurrent carboplatin-paclitaxel chemotherapy for stage Ⅲ non-small cell lung cancer.
• 著者・編者: Inoue, Kazuya; Hontsu, Shigeto; Miura, Sachiko; Asakawa, Isao; Tamamoto, Tetsuro; Yoshimine, Tadashi; Kimura, Hiroshi; Hasegawa, Masatoshi
• 著者標目: Inoue, Kazuya; Hontsu, Shigeto; Miura, Sachiko; Asakawa, Isao; Tamamoto, Tetsuro; Yoshimine, Tadashi; Kimura, Hiroshi; Hasegawa, Masatoshi
• 出版事項: 奈良医学会
• 出版年月日等: 2017-04
• 出版年（W3CDTF）: 2017-04
• 並列タイトル等: Ⅲ期非小細胞肺癌に対するカルボプラチン・パクリタキセル同時併用66Gy放射線治療の安全性と有効性について
• タイトル（掲載誌）: Journal of Nara Medical Association
• 巻号年月日等（掲載誌）: 68 1-2
• 掲載巻: 68
• 掲載号: 1-2
• ISSN（掲載誌）: ISSN : 1345-0069
• 授与機関名: 奈良県立医科大学
• 授与年月日: 2017-03-15
• 報告番号: 甲第663号
• 学位: 博士（医学）
• 本文の言語コード: eng
• 件名標目: Non-small cell lung cancer; Concurrent chemoradiotherapy; 66Gy; Carboplatin-paclitaxel chemotherapy
• 対象利用者: 一般
• 一般注記: type:Thesis; Purpose/Objectives: This study was conducted to assess the feasibility and efficacy of definitive radiotherapy (RT) with a total dose of 66Gy and concurrent carboplatin-paclitaxel chemotherapy for patients (pts) with stage Ⅲ non-small cell lung cancer. Materials/Methods: Between April 2007 and December 2013, 99 pts with non-small cell lung cancer were treated by RT with concurrent carboplatin-paclitaxel chemotherapy in our hospital. Sixty-eight of them received RT with a total dose of 66Gy. We analyzed 46 Stage Ⅲ pts who had been treated with RT using three-dimensional radiotherapy treatment planning. The prophylactic mediastinal lymph nodes were included in the clinical target volume of RT. The survival rate after the beginning of RT was estimated using the Kaplan-Meier method. We estimated the cumulative local failure and distant metastasis rates with the Fine-Gray method. Adverse events were evaluated according to the CTCAE (v.4.0). Results: The median age of the pts was 70.9 (52.8-78.7) years old (y.o.). The performance status (PS) of each pt was fairly good (ECOG PS 0: 25, PS 1: 20, PS3:1), and clinical stages (UICC 7th) consisted of twenty-nine ⅢA and seventeen ⅢB. Diagnoses were pathologically confirmed in 32 pts. The median follow-up period was 35.7 (2.0-82.2) months among all pts, and 55.9 (40.1-82.2) months among survivors. The 3- and 5-year Kaplan-Meier overall survival rates were 52.2 and 34.0%, respectively, and the median survival time was 36.6 months. The 3- and 5-year Kaplan-Meier progression-free survival rates were 29.1 and 21.9%, respectively, and the median progression-free survival time was 9.9 months. The 5-year local failure rate was 37.6%, and the 5-year distant metastasis rate was 49.7%. Sixteen (34.8%) pts required steroid administration because of radiation pneumonitis (CTCAE Grade 2 or higher) and two of them died (Grade 5). No other severe non-hematologic toxicity (Grade 3 or higher) was observed. Conclusion: These results suggest that definitive RT with a total dose of 66Gy and concurrent carboplatin-paclitaxel chemotherapy is feasible and may be promising for pts with Stage Ⅲ non-small cell lung cancer.; 博士（医学）・甲第663号・平成29年3月15日; identifier:Journal of Nara Medical Association Vol.68 No.1,2,3 p.1-6 (2017.06); identifier:13450069; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/3314; identifier:Journal of Nara Medical Association, 68(1-2)
• オンライン閲覧公開範囲: インターネット公開
• 連携機関・データベース: 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• 提供元機関・データベース: 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU

目次

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3314/1/01_%e7%94%b2663%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3314/2/02_%e7%94%b2663%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf fulltext

http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3314/14/03_%e7%94%b2663%e6%9c%ac%e6%96%87.pdf fulltext